Strengthening Swedish competitiveness in biological medicines
Vinnova invests another 12 million in three important centers for biological medicines. Thanks to these three centers, Sweden has established a good foundation for taking a leading position in biological medicines and advanced therapies.
The three centers will receive extended funding in the coming years with four million each.
- An important objective of the research program for biological medicines was to establish strong research and development environments in biological medicines in order to make Sweden a leader in the field. Today, the centers are important components of the Swedish ecosystem for biological medicines and advanced therapies. In this way, we complement other investments in the area and further strengthen Swedish competitiveness in the coming years, says Anders Brinne. area manager Sustainable precision health, Vinnova.
Background
The centers are part of an eight-year research program for biological medicines totaling SEK 320 million in the years 2016-2023. Vinnova and the Swedish Research Council have run the program, which is part of the government's strategic partnership programmes in life science.
In the centres, several of Sweden's largest pharmaceutical companies work together with smaller companies, universities and university colleges and actors in the health care sector, with research, development and innovation. The program will contribute to competence development, innovation and competitiveness with the goal that Sweden will be a leader in the development and production of biological medicines.
CAMP - Center for Advanced Medical Products
The first center in biological medicines in Sweden, which today is internationally recognized and has been the platform behind many important investments in the field. CAMP has an important role in gathering and coordinating Swedish actors to, for example, attract investments and take a place in the international arena.
In the centre, approx. 40 parties collaborate with Umeå University as coordinator. Center manager Jukka Lausmaa, jukka.lausmaa@umu.se
CellNova
The center conducts extensive research in areas relevant to the development of biological medicines. The research contributes important data to the development of new biological medicines.
In the centre, ten parties collaborate with KTH as coordinator.
Center manager Sophia Hober, sophia@biotech.kth.se
NextBioForm
The center works to improve formulation and processing for the production of biological drugs. They are developing important collaboration to bridge the gap between bioprocess and drug manufacturing.
In the centre, 18 parties collaborate with RISE as coordinator.
Center manager Anna Fureby, anna.fureby@ri.se
Questions?
Last updated 18 September 2023
Page statistics